International Journal of Hematology

, Volume 110, Issue 2, pp 250–254 | Cite as

Hereditary spherocytosis caused by copy number variation in SPTB gene identified through targeted next-generation sequencing

  • Woori Jang
  • Jiyeon Kim
  • Hyojin Chae
  • Myungshin KimEmail author
  • Kyung-Nam KohEmail author
  • Chan-Jeoung Park
  • Yonggoo Kim
Case Report


Hereditary spherocytosis (HS) is a heterogeneous genetic disorder characterized by spherocytosis on peripheral blood smear with hemolytic anemia, accompanied by signs of hemolysis. Herein, we report a 5-month-old Korean girl with HS resulting from a de novo 271 Kb microdeletion of 14q23.3. She presented with hemolytic anemia and mild splenomegaly. Spherocytosis was seen on examination of peripheral blood. Eosin-5′-maleimide (EMA) test and flow cytometric osmotic fragility test were positive. She had no relevant family history of spherocytosis. No pathogenic single nucleotide variants or small insertions/deletions were detected in HS-associated genes. Array comparative genomic hybridization analysis revealed a 271 Kb deletion at chromosome 14q23.3, encompassing the SPTB, CHURC1, GPX2, RAB15, FNTB, and MAX genes. We found a deletion affecting 5′ UTR, exon 1, and part of intron 1 of the SPTB gene using targeted next-generation sequencing (NGS) analysis, suggesting that NGS may be able to identify disease-causing copy number variations (CNVs), as well as small point mutations in HS patients. In addition, chromosomal microarray may be useful in defining combined deleted genes. Additional evaluations should thus be considered in the diagnosis of HS, especially when CNV is revealed as disease-causing abnormality.


Hereditary spherocytosis SPTB Deletion Next-generation sequencing Chromosomal microarray 



We are grateful to the patient and her parents. We thank The Catholic Genetic Laboratory Center for assisting us in carrying out this study and compiling this report. This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (2018M3A9E8020866) and Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea.

Compliance with ethical standards

Conflict of interest

All authors declare that there is no conflict of interest.


  1. 1.
    Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372:1411–26.CrossRefGoogle Scholar
  2. 2.
    Park J, Jeong DC, Yoo J, Jang W, Chae H, Kim J, et al. Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis. Clin Genet. 2016;90:69–78.CrossRefGoogle Scholar
  3. 3.
    Hassoun H, Vassiliadis JN, Murray J, Yi SJ, Hanspal M, Ware RE, et al. Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site precludes spectrin attachment to the membrane in hereditary spherocytosis. J Clin Invest. 1995;96:2623–9.CrossRefGoogle Scholar
  4. 4.
    Lybaek H, Oyen N, Fauske L, Houge G. A 2.1 Mb deletion adjacent but distal to a 14q21q23 paracentric inversion in a family with spherocytosis and severe learning difficulties. Clin Genet. 2008;74:553–9.CrossRefGoogle Scholar
  5. 5.
    Griswold AJ, Ma D, Sacharow SJ, Robinson JL, Jaworski JM, Wright HH, et al. A de novo 1.5 Mb microdeletion on chromosome 14q23.2–23.3 in a patient with autism and spherocytosis. Autism Res. 2011;4:221–7.CrossRefGoogle Scholar
  6. 6.
    Park SH, Park C-J, Lee B-R, Cho Y-U, Jang S, Kim N, et al. Comparison study of the eosin-5′-maleimide binding test, flow cytometric osmotic fragility test, and cryohemolysis test in the diagnosis of hereditary spherocytosis. Am J Clin Path. 2014;142:474–84.CrossRefGoogle Scholar
  7. 7.
    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRefGoogle Scholar
  8. 8.
    Park J, Jang W, Han E, Chae H, Yoo J, Kim Y, et al. Hereditary dehydrated stomatocytosis with splicing site mutation of PIEZO1 mimicking myelodysplastic syndrome diagnosed by targeted next-generation sequencing. Pediatr Blood Cancer. 2018;65:e27053.CrossRefGoogle Scholar
  9. 9.
    Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012;28:2747–54.CrossRefGoogle Scholar
  10. 10.
    Kerkhof J, Schenkel LC, Reilly J, McRobbie S, Aref-Eshghi E, Stuart A, et al. Clinical validation of copy number variant detection from targeted next-generation sequencing panels. J Mol Diagn. 2017;19:905–20.CrossRefGoogle Scholar
  11. 11.
    Povysil G, Tzika A, Vogt J, Haunschmid V, Messiaen L, Zschocke J, et al. panelcn.MOPS: Copy-number detection in targeted NGS panel data for clinical diagnostics. Hum Mutat. 2017;38:889–97.CrossRefGoogle Scholar
  12. 12.
    Ellingford JM, Campbell C, Barton S, Bhaskar S, Gupta S, Taylor RL, et al. Validation of copy number variation analysis for next-generation sequencing diagnostics. Eur J Hum Genet. 2017;25:719–24.CrossRefGoogle Scholar
  13. 13.
    Johansson LF, van Dijk F, de Boer EN, van Dijk-Bos KK, Jongbloed JD, van der Hout AH, et al. CoNVaDING: single exon variation detection in targeted NGS data. Hum Mutat. 2016;37:457–64.CrossRefGoogle Scholar
  14. 14.
    Fraiman YS, Moliterno AR. High-density genomic analysis reveals basis of spherocytosis in myelodysplastic syndrome. Blood. 2015;125:3517.CrossRefGoogle Scholar
  15. 15.
    Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.CrossRefGoogle Scholar
  16. 16.
    Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828–37.CrossRefGoogle Scholar
  17. 17.
    Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papathomas TG, van Nederveen FH, et al. Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis. J Clin Endocrinol Metab. 2016;101:453–60.CrossRefGoogle Scholar
  18. 18.
    Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Laboratory Medicine, College of Medicine, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Catholic Genetic Laboratory Center, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Department of Pediatrics, Asan Medical Center Children’s HospitalUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  4. 4.Department of Laboratory Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea

Personalised recommendations